A panel of expert oncologists reviews 2 clinical cases of HR+ breast cancer, discusses key clinical trial data, and outlines approaches to biomarker testing.
EP. 1: What to Test for in Patients With Early- or Late-Stage Breast Cancer
Opening their program on HR+/HER2- metastatic breast cancer, expert oncologists consider the growing list of therapeutic targets to test for in patients with early or late-stage disease.
EP. 2: Novel Testing Methodologies in Breast Cancer Management
Key opinion leaders provide insight on testing strategies, primarily circulating tumor DNA, in patients diagnosed with HR+/HER2- metastatic breast cancer.
EP. 3: What is the Role of Germline Testing in Patients With Breast Cancer?
Focused discussion on the evolving role of germline testing in HR+/HER2- metastatic breast cancer and how it may impact treatment pathways.
EP. 4: Patient Case 1: Mutated ESR1 in HR+/HER2- Metastatic Breast Cancer
Centering discussion on the first patient case, panelists reflect on the importance of ESR1 mutation in the setting of HR+/HER2- metastatic breast cancer.
EP. 5: Optimal ESR1 Testing Strategies in HR+/HER2- Metastatic Breast Cancer
In the context of ESR1 mutation in HR+/HER2- metastatic breast cancer, key opinion leaders consider ideal testing modalities and timing to improve patient outcomes.
EP. 6: HR+/HER2- Metastatic Breast Cancer: Impact of ESR1 Mutation on Treatment
Before closing out their module on ESR1 mutation, panelists identify its impact on treatment options for patients diagnosed with HR+/HER2- metastatic breast cancer.
EP. 7: Trial Data: 2L Therapy After ET + CDK4/6i in HR+/HER2- Metastatic Breast Cancer
Joyce O’Shaughnessy, MD, highlights key data from a number of clinical trials in the second-line treatment setting of HR+/HER2- metastatic breast cancer.
EP. 8: Considerations for Selecting and Sequencing Therapy in HR+/HER2- mBC
In light of the second-line treatment armamentarium for patients with HR+/HER2- metastatic breast cancer, expert oncologists discuss the selection and sequencing of specific agents in this setting.
EP. 9: EMERALD: Elacestrant in Relapsed/Refractory HR+/HER2- mBC
A focused review of data from the EMERALD study, which tested elacestrant, an oral SERD, in patients with HR+/HER2- metastatic breast cancer.
EP. 10: Relapsed/Refractory HR+/HER2- mBC: Real-World Applications of the EMERALD Trial
Expert panelists consider how they might apply data from the EMERALD study in their real-world management of HR+/HER2- metastatic breast cancer.
EP. 11: Patient Case 2: Unmutated HR+/HER2- Metastatic Breast Cancer
Expert perspectives on a second patient case of unmutated metastatic breast cancer and available treatment strategies in this setting.
EP. 12: TROPiCS-02: Sacituzumab Govitecan in Relapsed/Refractory HR+/HER2- mBC
Expert Joyce O’Shaughnessy, MD, reviews data from the TROPiCS-02 study of sacituzumab govitecan in HR+/HER2- metastatic breast cancer.
EP. 13: DESTINY-Breast04: T-DXd in HER2-Low Metastatic Breast Cancer
Following her review of TROPiCS-02, Joyce O’Shaughnessy, MD, shares data from the DESTINY-Breast04 study of T-DXd in HER2-low metastatic breast cancer.
EP. 14: Evolving Role of Antibody Drug Conjugates in Metastatic Breast Cancer
Key opinion leaders on breast cancer management share insight on the evolving role of antibody drug conjugates and their potential impact on care.
EP. 15: HR+/HER2- Metastatic Breast Cancer: Future Directions in Care
Closing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.
2 Clarke Drive Cranbury, NJ 08512